This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Micro Interventional Devices, Inc. Closes First Tranche Of $5 Million Series B Financing

BETHLEHEM, Pa., Jan. 14, 2013 /PRNewswire/ --  Micro Interventional Devices, Inc.™ (MID), an emerging cardiovascular medical device company, announced today it has secured $3.5 million of its expected $5 million Series B financing.  The initial tranche was led by Originate Ventures with existing investor, Battelle Ventures, LP, also participating in the round.  In conjunction with the financing Mike Gausling, Managing Partner of Originate Ventures, will join the MID Board of Directors.

The funding will be used to support the ongoing development of the Permaseal™ product, advance the STASIS clinical study (Sutureless Transapical Access and Closure Study) and obtain CE Mark approval for Permaseal.  The funding will also support MID's research and development initiatives focused on developing its percutaneous transapical and large bore femoral access and closure devices.

"The market for transcatheter aortic valve implantation is expected to grow rapidly over the next several years as innovation continues to improve and simplify the procedure," said Mike Gausling, Managing Partner of Originate Ventures. "Originate Ventures believes that Permaseal represents a significant opportunity given these market dynamics.  I am excited to be joining MID's Board of Directors and to work with management to ensure the successful clinical and commercial development of this revolutionary access and closure technology."

Permaseal is the first transapical access device to enable true "self-sealing," sutureless cardiac access and closure.  The device is designed to enable a range of structural heart repair procedures including transcatheter aortic valve implantation (TAVI) and mitral valve replacement and repair.   

"Closing the first tranche in our Series B, and the addition of Mike Gausling to MID's Board, are key milestones in the growth of MID and ongoing development of Permaseal," stated Michael Whitman, President and CEO of MID.  "As TAVI becomes more widespread there is a critical need for efficient cardiac access and closure devices. We believe the Permaseal platform is a true game-changing technology, and we look forward to completing the STASIS trial and securing CE Mark in order to fulfill this unmet therapeutic need."

About Micro Interventional Devices, Inc:Micro Interventional Devices, Inc. (MID) is an emerging cardiovascular medical device company founded in May 2010.  MID is developing solutions for transcatheter aortic valve implantation (TAVI), transcatheter mitral valve replacement and repair and other emerging structural heart repair procedures.  The company is developing proprietary technology based on a breakthrough in soft-tissue anchoring and associated delivery devices that enable off-pump procedures.  To learn more, please visit www.microinterventional.com.

Company Contact:Micro Interventional Devices, Inc. Katherine WhitmanMarketing Communications Manager kwhitman@microinterventional.com

Media Contact:Tiberend Strategic Advisors, Inc.(212) 827-0020 Claire Sojda csojda@tiberend.com

 

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 16,643.01 -11.76 -0.07%
S&P 500 1,988.87 +1.21 0.06%
NASDAQ 4,828.3250 +15.6170 0.32%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs